Monthly Archives: November 2016

Biothera Pharmaceuticals Announces Data Demonstrating Unique Immune Response Profile Generated by Phase 2 Cancer Immunotherapy Imprime PGG

Researchers to Present Preclinical Data at EORTC-NCI-AACR Symposium EAGAN, MN — November 29, 2016 — Biothera Pharmaceuticals, Inc. will present data tomorrow illustrating the unique cytokine response generated by its phase 2 cancer immunotherapy Imprime PGG, the only Pathogen Associated Molecular Patterning (PAMP) molecule that has been successfully administered systemically. The data will be highlighted in two poster presentations at the 28th EORTC-NCI-AACR Symposium on Molecular...

Read More


Biothera Pharmaceuticals Preclinical Data Further Validate Mechanism of its Phase 2 Cancer Immunotherapy, Imprime PGG

3 Poster Presentations Scheduled for Society for Immunotherapy of Cancer Annual Meeting EAGAN, MN — November 11, 2016 — Biothera Pharmaceuticals, Inc. will present new preclinical data today that further validate the ability of its Phase 2 cancer immunotherapy drug Imprime PGG to induce coordinated innate and adaptive immune responses that may enhance the efficacy of checkpoint inhibitor therapies. The data will be highlighted in three...

Read More


Preclinical Data Published in PLOS ONE Support Use of a Patient Selection Biomarker for Biothera Pharmaceuticals’ Phase 2 Cancer Immunotherapy Imprime PGG

Formation of Imprime PGG-Immune Complex Essential to Anti-Tumor Activity EAGAN, MN — November 7, 2016 — Biothera Pharmaceuticals, Inc. today announced the publication of preclinical research identifying an essential mechanism in the activation of anti-cancer immune responses by Imprime PGG, the Company’s Phase 2 cancer immunotherapy drug. The formation of an immune complex between Imprime PGG and endogenous anti-beta glucan antibodies (ABA) offers the potential...

Read More


MIT Research: Targeting Both Innate and Adaptive Immunity may be the Key to Enhancing the Effectiveness of Cancer immunotherapy

Last week scientists at the Massachusetts Institute of Technology provided compelling new preclinical research that large, aggressive tumors in mice could be eradicated by combining a series of immune therapies to activate both the innate and adaptive immune systems. Immunologic rejection of these large, advanced tumors was achieved through an orchestrated immune attack triggered by the rational combination of immune-modulatory agents, each of which was...

Read More